CA3007996A1 - Compositions and methods for treatment of her2 positive metastatic breast cancer - Google Patents

Compositions and methods for treatment of her2 positive metastatic breast cancer Download PDF

Info

Publication number
CA3007996A1
CA3007996A1 CA3007996A CA3007996A CA3007996A1 CA 3007996 A1 CA3007996 A1 CA 3007996A1 CA 3007996 A CA3007996 A CA 3007996A CA 3007996 A CA3007996 A CA 3007996A CA 3007996 A1 CA3007996 A1 CA 3007996A1
Authority
CA
Canada
Prior art keywords
cancer
activated
receptor
kit
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3007996A
Other languages
English (en)
French (fr)
Inventor
Shahrooz Rabizadeh
Patrick Soon-Shiong
Hans Klingemann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nant Holdings IP LLC
Immunitybio Inc
Original Assignee
Nant Holdings IP LLC
NantKwest Inc
NantCell Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nant Holdings IP LLC, NantKwest Inc, NantCell Inc filed Critical Nant Holdings IP LLC
Publication of CA3007996A1 publication Critical patent/CA3007996A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/49—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
CA3007996A 2015-12-09 2016-12-09 Compositions and methods for treatment of her2 positive metastatic breast cancer Pending CA3007996A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562265382P 2015-12-09 2015-12-09
US62/265,382 2015-12-09
PCT/US2016/066018 WO2017100709A1 (en) 2015-12-09 2016-12-09 Compositions and methods for treatment of her2 positive metastatic breast cancer

Publications (1)

Publication Number Publication Date
CA3007996A1 true CA3007996A1 (en) 2017-06-15

Family

ID=59013368

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3007996A Pending CA3007996A1 (en) 2015-12-09 2016-12-09 Compositions and methods for treatment of her2 positive metastatic breast cancer

Country Status (8)

Country Link
US (1) US20180360881A1 (cg-RX-API-DMAC10.html)
EP (1) EP3386522A4 (cg-RX-API-DMAC10.html)
JP (1) JP2018537536A (cg-RX-API-DMAC10.html)
KR (1) KR20180123214A (cg-RX-API-DMAC10.html)
CN (1) CN109475576A (cg-RX-API-DMAC10.html)
AU (1) AU2016366677A1 (cg-RX-API-DMAC10.html)
CA (1) CA3007996A1 (cg-RX-API-DMAC10.html)
WO (1) WO2017100709A1 (cg-RX-API-DMAC10.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4650005A3 (en) 2016-07-15 2026-01-28 Viracta Subsidiary, Inc. Histone deacetylase inhibitors for use in immunotherapy
CN110769898A (zh) * 2017-06-22 2020-02-07 南加利福尼亚大学 使用嵌合抗原受体工程化自然杀伤细胞作为化学治疗药物运载体的联合癌症疗法
US11510982B2 (en) 2017-08-15 2022-11-29 Nantcell, Inc. HaNK cetuximab combinations and methods
CN110484507B (zh) * 2018-01-31 2023-10-13 温州医科大学 一种靶向肿瘤Her2的新型嵌合抗原受体T细胞的制备技术
IL321548A (en) * 2018-05-22 2025-08-01 Immunitybio Inc Recombinant NK cells expressing a chimeric antigen receptor (CAR) for epsilon-FC and uses thereof
BR112021001750A2 (pt) * 2018-08-06 2021-04-27 Daiichi Sankyo Company, Limited composição farmacêutica
KR20240162586A (ko) * 2018-10-31 2024-11-15 난트퀘스트, 인크. Pd-l1 키메라 항원 수용체-발현 nk 세포에 의한 pd-l1-양성 악성종양의 제거
US20220265716A1 (en) * 2019-07-26 2022-08-25 Nantkwest, Inc. Antibody pre-loaded cd16+nk-92 cells as an effective therapeutic product for tumor lysis
KR102594083B1 (ko) 2020-07-07 2023-10-25 칸큐어 엘엘씨 Mic 항체 및 결합제 및 이의 사용 방법
CN112675313A (zh) * 2020-12-28 2021-04-20 烟台大学 连接曲妥珠单抗片段的美登素纳米粒组合物
IL311003A (en) 2021-08-25 2024-04-01 Denali Therapeutics Inc Anti-2HER antibodies and methods of using them
CN114807237A (zh) * 2022-05-12 2022-07-29 广东普罗凯融生物医药科技有限公司 一种过表达CD16a的NK细胞的制备方法及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040105740A (ko) * 2002-02-25 2004-12-16 엘란 파마슈티칼스, 인크. 염증 치료제의 투여 방법
JP5295568B2 (ja) * 2005-01-06 2013-09-18 ノヴォ ノルディスク アー／エス Ｋｉｒ結合剤およびその使用方法
JP5838021B2 (ja) * 2005-04-15 2015-12-24 マクロジェニクス，インコーポレーテッド 共有結合型ダイアボディとその使用
EP2161339A1 (en) * 2008-08-29 2010-03-10 F. Hoffmann-La Roche Ag ADCC with modified NK92 cells
EP3701957B1 (en) * 2013-11-01 2022-12-28 ImmunityBio, Inc. Tumoricidal and antimicrobial compositions and methods
CN113699159A (zh) * 2014-03-28 2021-11-26 明尼苏达大学评议会 涉及经工程改造的cd16的多肽、细胞和方法
CA2980592A1 (en) * 2015-03-27 2016-10-06 Nantkwest, Inc. Nk-92 cells in combination therapy with cancer drugs

Also Published As

Publication number Publication date
JP2018537536A (ja) 2018-12-20
WO2017100709A1 (en) 2017-06-15
AU2016366677A1 (en) 2018-07-26
EP3386522A4 (en) 2019-06-19
US20180360881A1 (en) 2018-12-20
CN109475576A (zh) 2019-03-15
EP3386522A1 (en) 2018-10-17
KR20180123214A (ko) 2018-11-15

Similar Documents

Publication Publication Date Title
US20180360881A1 (en) Compositions and Methods for Treatment of Her2 Positive Metastatic Breast Cancer
García-Foncillas et al. Distinguishing features of cetuximab and panitumumab in colorectal cancer and other solid tumors
AU2020301161B2 (en) FLT3L-Fc fusion proteins and methods of use
Vacchelli et al. Trial Watch: Chemotherapy with immunogenic cell death inducers
TWI895708B (zh) 用於治療ｔｒｏｐ－２表現性癌症之組合療法
KR100386492B1 (ko) 괴사유발물질과괴사에의해활성화되는물질을함유하는,종양및염증질환치료용배합제제로서의약제학적조성물
AU2014330895B2 (en) Combination tumor treatment with drug-loaded, bispecific ligand-targeted minicells and interferon-gamma
US20220273722A1 (en) Anti-egfr/high affinity nk-cells compositions and methods for chordoma treatment
WO2017165439A1 (en) Methods for improving the therapeutic index for a chemotherapeutic drug
US20200016283A1 (en) Combination therapy comprising a radiopharmaceutical and a dna-repair inhibitor
US11617797B2 (en) Multi-targeted multi-valent ligand drug particles for the treatment and prevention of diseases and conditions
US20250043023A1 (en) Targeting moiety-drug grafted immune cell compositions and methods of use
Seong et al. New therapeutics for soft tissue sarcomas: overview of current immunotherapy and future directions of soft tissue sarcomas
Kim et al. Current trends and innovative approaches in cancer immunotherapy
Smolarska et al. Targeted therapies for glioblastoma treatment.
WO2017139468A1 (en) Combination of ifn-gamma with erbb inhibitor for the treatment of cancers
CN105050619A (zh) 用于治疗her2-阳性癌症的组合疗法
CA3073744A1 (en) Aldoxorubicin combination treatments and methods
WO2022192372A1 (en) Methods and compositions for tusc2 combination therapy with pdk1 inhibition
JP7780824B2 (ja) Ｈｅｒ２ワクチン組成物
CA3073045A1 (en) Hank cetuximab combinations and methods
Assenmacher et al. The IAP antagonist birinapant enhances chimeric antigen receptor T cell therapy for glioblastoma by overcoming antigen heterogeneity
Zhou Development and Evaluation of LSR-and CD276-Targeted Therapies for Triple-Negative Breast Cancer
EP4727978A2 (en) Compositions comprising anti-mutant kras antibodies and methods of use thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20211208